Theranostic Applications of Radionuclides in Prostate Cancer

Recruiting now · Not applicable

Conditions studied: Prostate Cancer (Diagnosis)

In brief

The objective of the study is to construct a noninvasive approach ACP3 targeted PET/CT to detect tumor lesions in patients with prostate cancer and to compare with PSMA/FDG PET/CT.

Key facts

Study ID

NCT07559201

Run by

Guilin Medical University, China

People needed

100

Starts

2026-01-01

Expected to finish

2029-12-31

Last updated by the study team

2026-04-30

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Adult patients (aged 18 years or older);
• Patients with newly diagnosed, highly suspected recurrence or previously treated metastases of prostate cancer (supporting evidence may include MRI, CT, tumor markers, and pathology report);
• Patients who had scheduled both standard-of-care imaging (PSMA/FDG PET/CT) and ACP3 PET/CT scans;
• Patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.

You may not qualify if…

• The inability or unwillingness of the research participant or legal representative to provide written informed consent.

Where it is running

• The First Affliated Hospital of Guilin Medical University — Guilin, Guangxi, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.